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ABSTRACT
We report herein the synthesis and physical and
physiological characterization of fully modified
2’-modified-4’-thioRNAs, i.e. 2’-fluoro-4’-thioRNA
(F-SRNA) and 2’-O-Me-4’-thioRNA (Me-SRNA),
which can be considered as a hybrid chemical
modification based on 2’-modified oligonucleotides
(ONs) and 4’-thioRNA (SRNA). In its hybridization
with a complementary RNA, F-SRNA (15mer)
showed the highest Tm value (+168C relative to the
natural RNA duplex). In addition, both F-SRNA and
Me-SRNA preferred RNA as a complementary part-
ner rather than DNA in duplex formation. The results
of a comprehensive comparison of nuclease stabil-
ity of single-stranded F-SRNA and Me-SRNA along
with 2’-fluoroRNA (FRNA), 2’-O-MeRNA (MeRNA),
SRNA, and natural RNA and DNA, revealed that
Me-SRNA had the highest stability with t1/2 values
of>24h against S1 nuclease (an endonuclease)
and 79.2min against SVPD (a 3’-exonuclease). More-
over, the stability of Me-SRNA was significantly
improved in 50% human plasma (t1/2=1631min)
compared with FRNA (t1/2=53.2min) and MeRNA
(t1/2=187min), whose modifications are currently
used as components of therapeutic aptamers. The
results presented in this article will, it is hoped,
contribute to the development of 2’-modified-
4’-thioRNAs, especially Me-SRNA, as a new RNA
molecule for therapeutic applications.
INTRODUCTION
A large number of chemically modiﬁed oligonucleotides
(ONs) have been synthesized for use in nucleic-acid-based
therapeutics (1). The discovery of RNA interference
(RNAi) has reinvigorated interest in this trend (2).
Chemically modiﬁed ONs are required especially to have
resistance toward nuclease degradation and thermal sta-
bility of duplex formation for their in vivo applications.
Among the modiﬁed ONs developed so far, a series of
20-modiﬁed ONs appears to be the most promising due
to their higher nuclease resistance and favorable hybrid-
ization with complementary RNA (3). For example,
20-ﬂuoroRNA (FRNA) and 20-O-MeRNA (MeRNA) are
the most typical modiﬁcations (4–6). When 20-hydroxy
groups in RNA are substituted, these modiﬁed RNAs
are highly resistant to nuclease degradation, especially
toward ribonuclease (RNase) digestion. In addition,
such modiﬁcations force the ONs to adopt a higher pro-
portion of the northern conformation in a helical struc-
ture, which is one of the contributing factors of stronger
hybridization property of these modiﬁed ONs. Because
of such favorable properties, these ONs are currently
used as components of therapeutic aptamers, such as
Macugen (7).
Whereas chemical modiﬁcation is carried out at the
20-position of ONs, the 40-position, namely the furanose
ring oxygen, has currently been recognized as an alterna-
tive modiﬁcation site. Our group has been intensely
studying the synthesis and application of a series of
40-thionucleic acids (40-thioRNA and 40-thioDNA),
which consist of 40-thioribonucleosides (8) and 20-deoxy-
40-thioribonucleosides (9). Since 40-thioRNA (SRNA) and
40-thioDNA (SDNA) exhibited nuclease resistance, high
hybridization and structural similarity to the A-form
RNA duplexes (10–12), applications of these ONs for
isolating the SRNA aptamers by SELEX (13,14) are
now under investigation as well as the development of
tools for gene silencing via RNAi machinery (15–17). As
part of our research project, we envisioned synthesiz-
ing 20-modiﬁed-40-thioRNAs, i.e. 20-ﬂuoro-40-thioRNA
(F-SRNA) and 20-O-Me-40-thioRNA (Me-SRNA)
(Figure 1), which can be considered as a hybrid chemical
modiﬁcation based on the 20-modiﬁed ONs and SRNA.
These new ONs are expected to show synergic eﬀects on
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resistance.
Herein we describe the synthesis of 20-modiﬁed-
40-thioRNAs and their characterization including their
hybridization and nuclease resistance. Thus far, numerous
chemically modiﬁed ONs have been developed and their
properties were investigated. However, these studies were
generally carried out individually, furnishing no compre-
hensive comparison with other known modiﬁed ONs
developed so far. Accordingly, we compared the proper-
ties of the newly prepared 20-modiﬁed-40-thioRNAs with
other ONs including FRNA, MeRNA and SRNA, the
details of which are discussed below.
MATERIALS AND METHODS
General methods
Physical data were measured as follows:
1H,
13C and
31P
NMR spectra were recorded at 270 and 400, and 500MHz
instruments, respectively, in CDCl3, DMSO-d6,o rD 2Oa s
the solvent with tetramethylsilane or H3PO4 (for
31P
NMR) as an internal standard. Chemical shifts are
reported in parts per million (d), and signals are expressed
as s (singlet), d (doublet), t (triplet), q (quartet), m (multi-
plet) or br (broad). Mass spectra were measured on JEOL
JMS-HX110 spectrometer. TLC was done on Merck
Kieselgel F254 precoated plates. Silica gel used for
column chromatography was Merck silica gel 5715. S1
nuclease and SVPD were purchased from TaKaRa and
MB Biomedicals, respectively. [g-
32P]ATP was purchased
from Perkin Elmer.
Synthesis of phosphoroamidite units
Synthetic protocols shown in Schemes 1 and 2 were
highlighted in this article. Protocols for synthesis of the
other units along with CPG support for F-SRNA and
Me-SRNA synthesis were given in the Supplementary
Data (Schemes S1, S2 and S3).
1-(2-O-Methyl-4-thio- -D-ribofuranosyl)uracil (2). To a
solution of 1 (9) (3.0g, 12mmol) in MeOH (120ml) were
added trimethyl borate (64% in MeOH, 4.0ml, 24mmol),
trimethyl orthoformate (1.4ml, 12mmol) and sodium
bicarbonate (83mg). The reaction mixture was heated for
48h at 1508C in a steel container. The reaction mixture was
cooled to room temperature and concentrated in vacuo.
The residue was puriﬁed by a silica gel column, eluted
with MeOH in CHCl3 (0–5%), to give 2 (2.9g, 86%) as a
white foam. An analytical sample was crystallized from
EtOH: mp, 1778C; FAB-LRMS m/z 275 (MH
+);
1H
NMR (D2O) d: 8.12 (d, 1H, J=8.1Hz), 5.89 (d, 1H,
J=4.8Hz), 5.77 (d, 1H, J=8.1Hz), 4.17 (dd, 1H,
J=4.3 and 5.0Hz), 3.92 (dd, 1H, J=4.3 and 5.0Hz),
3.78 (dd, 1H, J=4.8 and 12Hz), 3.71 (dd, 1H, J=5.4
and 12Hz), 3.38 (s, 3H), 3.36–3.33 (m, 1H);
13C NMR
(DMSO-d6) d: 162.8, 150.8, 141.2, 102.1, 85.3, 70.0, 62.6,
60.6, 57.6, 54.3. Anal. Calcd for C10H14N2O5S: C, 43.79;
H, 5.14; N, 10.21. Found: C, 43.78; H, 5.03; N, 10.24.
2,6-Diamino-9-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,
3-diyl)-4-thio- -D-furanosyl]-9H-purine (4). Compound 3
(1.4g, 2.0mmol) (8) was dissolved in ethanolic ammonia
(saturated at 08C, 80ml), and the mixture was heated at
1008C for 7.5h in a steel container. The solvent was
removed in vacuo. The residue was dissolved in MeNH2
in MeOH (40%, 60ml), and the mixture was kept at room
temperature for 1.5h. The solvent was removed, and the
residue was coevaporated with MeOH. The residue was
puriﬁed by a silica gel column, eluted with MeOH in
CHCl3 (0–3%), to give 4 (812mg, 75%) as a white solid:
FAB-LRMS m/z 541 (MH
+); FAB-HRMS calcd for
C22H41N6O4SSi2 (MH
+) 541.2448, found 541.2446;
1H
NMR (DMSO-d6) d: 7.89 (s, 1H), 6.78 (br s, 2H), 5.90
(d, 1H, J=4.5Hz), 5.86 (br s, 2H), 5.47 (s, 1H), 4.35
(dd, 1H, J=3.0 and 9.4Hz), 4.09 (m, 1H), 4.03–4.00
(m, 2H), 3.62–3.60 (m, 1H), 1.06–0.84 (m, 28H);
13C
NMR (DMSO-d6) d: 160.3, 156.1, 151.4, 134.7, 113.3,
77.5, 72.3, 60.6, 58.2, 48.5, 17.4, 17.2, 17.2, 16.8, 16.7,
12.6, 12.6, 12.5, 11.8.
2,6-Diamino-9-[2-O-methyl-3,5-O-(1,1,3,3-tetraisopropyl-
disiloxane-1,3-diyl)-4-thio- -D-ribofuranosyl]purine
(5). To a mixture of 4 (1.6g, 3.0mmol) and methyl iodide
(1.3ml, 21mmol) in dry DMF (30ml) was added NaH
(60% in oil, 600mg, 15mmol) at –408C. After being stir-
red for 2.5h at the same temperature, the reaction was
quenched by addition of saturated aqueous NH4Cl. The
solvent was removed in vacuo. The residue was diluted
with CHCl3, which was washed with H2O and saturated
aqueous NH4Cl, followed by brine. The organic layer was
dried (Na2SO4) and concentrated in vacuo. The residue
was puriﬁed by a silica gel column, eluted with MeOH
in CHCl3 (0–2%), to give 5 (1.4g, 85%) as a white
foam: FAB-LRMS m/z 555 (MH
+); FAB-HRMS calcd
for C23H43N6O4SSi2 (MH
+) 555.2596, found 555.2595;
1H NMR (DMSO-d6) d: 8.13 (s, 1H), 5.71 (s, 1H), 5.50
and 4.79 (each br s, each 2H), 4.42 (dd, 1H, J=3.4 and
9.7Hz), 4.15 (dd, 1H, J=2.8 and 12.6Hz), 3.83 (d, 1H,
J=3.4Hz), 3.71 (s, 3H), 3.68 (dd, 1H, J=2.8 and
9.7Hz), 1.15–0.84 (m, 28H);
13C NMR (CDCl3) d:
159.7, 155.8, 151.8, 137.1, 114.9, 87.2, 72.3, 59.4, 58.8,
57.9, 49.3, 17.4, 17.3, 17.1, 17.0, 16.9, 13.2, 13.1, 13.0, 12.3.
6-Amino-2-isobutyrylamino-9-[2-O-methyl-3,5-O-(1,1,3,
3-tetraisopropyldisiloxane-1,3-diyl)-4-thio- -D-ribofurano-
syl]purine (6). A solution of 5 (250mg, 0.44mmol) in dry
Figure 1. Design of 20-modiﬁed-40-thioRNAs.
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bath, and isobutyryl chloride (55ml, 0.53mmol) was
added dropwise to the stirred solution over a period of
10min at the same temperature. The reaction mixture
was stirred for 2h at the same temperature followed by
2h at room temperature. The reaction was quenched by
addition of ethanol. The solvent was removed in vacuo,
and the residue was diluted with CHCl3, which was
washed with H2O and saturated aqueous NaHCO3, fol-
lowed by brine. The organic layer was dried (Na2SO4) and
concentrated in vacuo. The residue was puriﬁed by a silica
gel column, eluted with MeOH in CHCl3 (0–2%), to give 6
(230mg, 83%) as a white foam: FAB-LRMS m/z 625
(MH
+); FAB-HRMS calcd for C27H49N6O5SSi2 (MH
+)
625.3024, found 625.3032;
1H NMR (DMSO-d6) d: 9.81
(br s, 1H), 8.14 (s, 1H), 7.26 (br s, 2H), 5.72 (s, 1H), 4.33
(dd, 1H, J=3.2 and 9.7Hz), 4.03–4.02 (m, 3H), 3.63
(s, 3H), 4.60–3.58 (m, 1H), 2.93 (m, 1H), 1.10–0.78
(m, 34H);
13C NMR (CDCl3) d: 180.1, 156.9, 153.1,
149.9, 138.9, 117.1, 87.2, 72.5, 59.5, 59.4, 57.8, 49.1,
33.6, 19.3, 19.2, 17.4, 17.3, 17.0, 17.0, 16.8, 13.2, 13.2,
13.1, 13.0, 12.9, 12.3.
N
2-Isobutyryl-9-(2-O-methyl-4-thio- -D-ribofuranosyl)-
guanine (7). To a solution of 6 (340mg, 0.55mmol) in a
mixture of AcOH-H2O (2:1, 9ml) was added NaNO2
(600mg, 8.8mmol), and the mixture was stirred at room
temperature. After 30min, additional NaNO2 (1.2g,
18mmol) was added, and the reaction mixture was stirred
for additional 38h at the same temperature. The reaction
was neutralized with NaHCO3. The mixture was ﬁltered
through a Celite pad and washed with CHCl3. The ﬁltrate
was diluted with CHCl3, which was washed with H2O
and saturated aqueous NaHCO3, followed by brine.
The organic layer was dried (Na2SO4) and concentrated
in vacuo. The residue was dissolved in dry CH2Cl2
(6ml), and Et3N 3HF (270ml, 1.6mmol), Et3N (460ml,
3.3mmol) were added to the solution. The mixture was
stirred for 8h at room temperature. The solvent was
removed, and the residue was coevaporated with MeOH.
The resulting precipitate was ﬁltered, washed with MeOH
and dried to give 7 (153mg, 73% in two steps) as a white
solid: FAB-LRMS m/z 384 (MH
+); FAB-HRMS calcd
for C15H22N5O5S (MH
+) 384.1341, found 384.1349;
1H
NMR (DMSO-d6) d: 12.6 (br s, 1H), 11.6 (br s, 1H), 8.39
(s, 1H), 5.87 (d, 1H, J=7.3Hz), 7.38 (d, 1H, J=4.5Hz)
5.21 (t, 1H, J=5.7Hz), 4.40 (m, 1H), 4.30 (dd, 1H,
J=3.2 and 7.3Hz), 3.74–3.73 (m, 1H), 3.60–3.57
(m, 1H), 3.28 (m, 4H), 2.76–2.73 (m, 1H), 1.10, 1.12
(each s, each 3H);
13C NMR (DMSO-d6) d: 180.1, 154.7,
149.0, 148.2, 137.9, 119.8, 85.9, 69.8, 63.1, 58.4, 57.7, 53.6,
34.7, 18.8, 18.8.
N
2-Isobutyryl-9-[-5-O-(4,40-dimethoxytrityl)-2-O-methyl-
4-thio- -D-furanosyl]guanine (8). To a solution of 7
(150mg, 0.40mmol) in dry pyridine (4ml) was added
DMTrCl (202mg, 0.60mmol), and the reaction mixture
was stirred for 2h at room temperature. The reaction
was quenched by addition of ice. The mixture was con-
centrated in vacuo. The residue was diluted with AcOEt,
which was washed with H2O and saturated aqueous
NaHCO3, followed by brine. The organic layer was
dried (Na2SO4) and concentrated in vacuo. The residue
was puriﬁed by a silica gel column, eluted with MeOH
in CHCl3 (0–5%), to give 8 (282mg, quant.) as a white
foam: FAB-LRMS m/z 686 (MH
+); FAB-HRMS calcd
for C36H40N5O7S (MH
+) 686.2648, found 686.2650;
1H
NMR (CDCl3) d: 12.1 (br s, 1H), 8.94 (br s, 1H), 7.91
(s, 1H), 7.50–7.20 (m, 9H), 6.83–6.81 (m, 4H), 5.87 (d,
1H, J=5.1Hz), 4.34 (m, 1H), 4.22 (t, 1H, J=5.1Hz),
3.77 (s, 6H), 3.66–3.63 (m, 1H), 3.48 (dd, 1H, J=4.5
and 9.7Hz), 3.41 (s, 3H), 3.38 (dd, 1H, J=6.3 and
9.7Hz), 2.93 (br s, 1H), 2.37–2.31 (m, 1H), 1.10–1.07 (m,
6H);
13C NMR (CDCl3) d: 178.9, 158.6, 155.5, 148.4,
147.5, 144.5, 138.2, 135.6, 135.5, 130.0, 128.0, 127.9,
127.0, 121.6, 113.2, 87.5, 86.6, 73.1, 64.9, 60.0, 58.8,
55.2, 50.5, 36.1, 18.8, 18.7.
N
2-Isobutyryl-9-[3-O-{2-cyanoethoxy(diisopropylamino)
phosphino}-5-O-(4,40-dimethoxytrityl)-2-O-methyl-4-thio-
 -D-furanosyl]guanine (9). To a solution of 8
(1.5g, 2.1mmol) in dry CH2Cl2 (21ml) were added
N,N-diisopropylethylamine (0.95ml, 5.4mmol), DMAP
(33mg, 0.27mmol) and 2-cyanoethyl N,N-diisopropyl-
chlorophosphoramidite (0.91ml, 4.1mmol), and the reac-
tion mixture was stirred for 4h at 08C. The reaction was
quenched by addition of ice. The reaction mixture was
diluted with AcOEt, which was washed with H2O and
saturated brine. The organic layer was dried (Na2SO4)
and concentrated in vacuo. The residue was puriﬁed by a
silica gel column, eluted with hexane/AcOEt (1:1), to give
9 (1.4g, 73%) as a white foam: FAB-LRMS m/z 886
(MH
+); FAB-HRMS calcd for C45H57N7O8PS (MH
+)
886.3727, found 886.3716;
31P NMR (CDCl3) d: 151.3
and 149.1.
Synthesis of ONs
Support bound chemically modiﬁed ONs were synthesized
on an Applied Biosystem 3400 DNA synthesizer using the
corresponding phosphoramidite units at a 1.0mmol scale
following the standard procedure described for oligoribo-
nucleotides. Each of phosphoramidite units was used at
concentration of 0.1M in dry acetonitrile, and the cou-
pling time was extended to 10min for each step. After
completion of the synthesis, the CPG support was treated
with concentrated NH4OH or NH4OH/EtOH (3:1) at
558C for 16h. In the case of CPG supports loaded
FRNA1, FRNA2 and F-SRNA2, these were treated
with methanolic ammonia (saturated at 08C) at room tem-
perature for 24h. Then, the support was ﬁltered oﬀ. The
ﬁltrate was concentrated and the ON protected by a
DMTr group at the 50-end was chromatographed on a
C-18 silica gel column with a linear gradient of acetonitrile
(from 5% to 40%) in 0.1N TEAA buﬀer (pH 7.0). The
fractions containing the full-length ON were combined
and concentrated. The residue was treated with aqueous
acetic acid (70%) for 20min at room temperature. The
solution was concentrated and the residue was puriﬁed
on reversed-phase HPLC, using a J0sphere ODS-M80
column (4.6 150mm, YMC) with a linear gradient
of acetonitrile (from 10% to 40%) in 0.1N TEAA
Nucleic Acids Research,2009, Vol.37, No. 4 1355buﬀer (pH 7.0). The structure of each RNA was con-
ﬁrmed by measurement of MALDI-TOF/MASS spectro-
metry on a Voyager-DE pro. MeRNA1: calculated mass,
C157H206N55O103P14 4942.89 (M–H); observed mass,
4946.24. MeRNA2: calculated mass, C155H205N50O103P14
4847.86 (M–H); observed mass, 4847.36. FRNA1: cal-
culated mass, C142H161F15N55O88P14 4762.59 (M–H);
observed mass, 4753.7. FRNA2: calculated mass,
C140H160F15N50O88P14 4667.56 (M–H); observed mass,
4669.50. SRNA2: calculated mass, C140H175N50O88P14S15
4877.28 (M–H); observed mass, 4880.65. Me-SRNA1:
calculated mass, C157H206N55O88P14S15 5182.54 (M–H);
observed mass, 5180.99. F-SRNA2: calculated mass,
C140H160F15N50O73P14S15 4907.22 (M–H); observed
mass, 4907.02.
Determination of hybridization ability
Thermally induced transitions were monitored at 260nm
on a Beckman DU 650 spectrophotometer. Samples were
prepared as follows. Duplex formation: a solution con-
taining an appropriate ON and a complementary sequence
(3mM each) in a buﬀer of 10mM Na cacodylate (pH 7.0)
containing 100mM NaCl were heated at 908C for 5min,
then cooled gradually to room temperature and used for
the thermal denaturation study. The sample temperature
was increased 0.58C/min.
Circulardichroism (CD) measurements
CD spectra were obtained at 258C on a Jasco J720. The
solution containing samples (3mM each) in a buﬀer of
10mM Na cacodylate (pH 7.0) containing 100mM NaCl
was prepared, and the sample spectra were subtracted
from the buﬀer spectrum. The molar ellipticity was calcu-
lated from the equation [ ]= /cl, where   is the relative
intensity, c the sample concentration and l the cell path
length in centimeters.
AssaysforS1nuclease stability
Each RNA sample labeled with
32P at the 50-end (5 pmol)
was mixed with the corresponding unlabeled RNA
(100 pmol). The RNA sample was incubated in S1
nuclease buﬀer (30mM sodium acetate, 0.28M NaCl,
1mM ZnSO4, pH 4.6) supplemented with S1 nuclease
(0.17U/mlo r5 1U / ml) at 378C. At appropriate periods,
2ml aliquots of the reaction mixture were added to 10ml
of loading buﬀer (1  TBE, 7M urea, 0.05% bromophenol
blue, 0.05% xylene cyanol). The mixtures were then ana-
lyzed by electrophoresis on 20% polyacrylamide gel con-
taining 7M urea. Radioactive densities of the gel were
visualized by a Bio-imaging analyzer (Bas 2500, Fuji
Co., Ltd).
AssaysforSVPD stability
Each RNA sample labeled with
32P at the 50-end (5 pmol)
was mixed with the corresponding unlabeled RNA (100
pmol). The RNA sample was incubated in a buﬀer
(40mM Tris–HCl, 8mM MgCl2, 5mM DTT, pH 7.5)
supplemented with SVPD (6.8 10
 5 U/ml) at 378C. At
appropriate periods, 2ml aliquots of the reaction mixture
were added to 10ml of loading buﬀer (1  TBE, 7M urea,
0.05% bromophenol blue, 0.05% xylene cyanol). The mix-
tures were then analyzed by electrophoresis on 20% poly-
acrylamide gel containing 7M urea. Radioactive densities
of the gel were visualized by a Bio-imaging analyzer (Bas
2500, Fuji Co., Ltd).
Assays forhuman plasmastability
Each RNA sample labeled with
32P at the 50-end (5 pmol)
was mixed with the corresponding unlabeled RNA (100
pmol). The RNA sample was incubated in PBS (40ml)
containing 50% human plasma at 378C. At appropriate
periods, 3ml aliquots of the reaction mixture were added
to 16ml of loading buﬀer (1 TBE, 7M urea, 0.05% bro-
mophenol blue, 0.05% xylene cyanol). The mixtures were
then analyzed by electrophoresis on 20% polyacrylamide
gel containing 7M urea. Radioactive densities of the gel
were visualized by a Bio-imaging analyzer (Bas 2500, Fuji
Co., Ltd).
RESULTS AND DISCUSSION
Chemistry
As reported in our previous article (18), we have synthe-
sized 20-deoxy-20-ﬂuoro-40-thiouridine, -thiocytidine and -
thioadenosine, the components of F-SRNA. However,
despite further attempts to prepare 20-deoxy-20-ﬂuoro-40-
-thioguanosine, we did not obtain the desired compound
in suﬃcient quantity to carry out ON synthesis. For the
synthesis of a series of 20-O-Me-40-thioribonucleosides, the
components of Me-SRNA, uridine, cytidine, adenosine
and guanosine derivatives were all prepared according to
methods similar to those used for their 40-O-congener
(19,20). Thus, treatment of 2,20-O-anhydro-40-thiouridine
(1) (9) with a mixture of trimethyl borate and trimethyl
orthoformate in the presence of a catalytic amount of
sodium bicarbonate aﬀorded 20-O-Me-40-thiouridine (2)
in 86% yield (Scheme 1). The resulting 2 was converted
into its cytosine derivative, and then the corresponding
phosphoramidite units, respectively, using the standard
procedure (details of the synthetic scheme and experimen-
tal procedures are given in the Supplementary Data;
Scheme S2). In the case of the purine derivatives, a
direct methylation of the 20-hydroxy group was employed.
In Scheme 2, the synthesis of the 20-O-Me-40-thiogua-
nosine units is shown as an example, since the chemical
conversion of the nucleobase diﬀers slightly from that of
our previous method (10). Thus, immediately after
the Pummerer reaction (8), compound 3 was heated in
Scheme 1.
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ature to give the diamino derivative 4. When the resulting
4 was treated with MeI in DMF in the presence of NaH
at –408C, the 20-O-Me derivative 5 was obtained in 85%
yield. Selective protection of the 2-amino group of 5 by
isobutyryl chloride aﬀorded 6. The remaining 6-amino
group of 6 was then hydrolyzed via diazotization to give
the guanine derivative. Since a partial deprotection of the
TIPDS group on the sugar portion took place during the
reaction, the resulting mixture was subsequently treated
with Et3N 3HF to give 7 in 73% yield in two steps.
Protection of the 50-hydroxy group with a dimethoxytrityl
(DMTr) group, followed by reaction with N,N-diisopro-
pylchlorophosphoramidite in the presence of Hu ¨ nig0s base
aﬀorded the 20-O-Me-40-thioguanosine phosphoramidite
unit 9. The corresponding adenosine unit was also pre-
pared in a similar manner (details of the synthetic
scheme and experimental procedures are given in the
Supplementary Data; Scheme S3). Using these phosphor-
amidite units, we synthesized 20-modiﬁed-40-thioRNAs
along with other ONs in a DNA/RNA synthesizer
following the standard procedure. The sequences used in
this study are shown in Figure 2. The series of ON1s
includes Me-SRNA (Me-SRNA1), which is the same as
that used in our previous report (10), while the sequence
of ON2s includes F-SRNA (F-SRNA2), since the
40-thioguanosine phosphoramidite unit of this modiﬁed
ON was not available. For a comprehensive comparison
of their properties, MeRNAs (MeRNA1 and MeRNA2),
FRNAs (FRNA1 and FRNA2), and SRNAs [SRNA1
(10) and SRNA2] along with natural RNAs (RNA1 and
RNA2) and DNAs (DNA1 and DNA2) were also
prepared.
Duplexstability and structural aspects
The thermal stabilities of the synthetic ONs with comple-
mentary RNA (cRNA1 or cRNA2) and DNA (cDNA1 or
cDNA2) were measured by ultraviolet melting experi-
ments in a buﬀer of 10mM sodium cacodylate (pH 7.0)
containing 100mM NaCl (Table 1). A duplex of
RNA1:cRNA1 had a Tm value of 66.28C and that of
DNA1:cRNA1 showed a lower Tm value (56.28C and
Tm=–108C). When RNA1 was changed to the modiﬁed
RNAs, the duplexes were all stabilized compared to
RNA1:cRNA1. Among the duplexes examined (a series
of ON1:cRNA1), FRNA1:cRNA1 showed the highest
Tm value (77.48C, DTm=+11.28C). The rank order
of the Tm’s with the complementary RNA (cRNA1)
was FRNA>Me-SRNA=SRNA>MeRNA>RNA>
DNA, where the order of FRNA>MeRNA>RNA>
DNA was identical with that of the previous report (6).
Although there was no synergistic eﬀect in Me-SRNA1 in
terms of hybridization with RNA, the advantage of this
modiﬁed RNA was obvious from the comparison of the
Tm values of ON1:cRNA1 with those of ON1:cDNA1, to
wit, the modiﬁed ONs, which hybridize with RNA, gen-
erally form a stable duplex with DNA. In fact, both
MeRNA1 and FRNA1 formed a thermally stable duplex
with cDNA1 just as they did with cRNA1. On the other
hand, Me-SRNA1 formed a less stable duplex with
cDNA1 (42.48C; Tm= 9.28C). Thus, the rank order
of the Tm values with the complementary DNA
(cDNA1) was changed to the following: FRNA>
DNA>MeRNA>RNA>SRNA>Me-SRNA. As we
previously reported (10), this property is charac-
teristic of SRNA (SRNA1:cRNA1=73.38C versus
SRNA1:cDNA1=43.68C; Tm=29.78C), and was
further enhanced by methylation of the 20-OH group,
namely Me-SRNA (Me-SRNA1:cRNA1=73.38C versus
Me-SRNA1:cDNA1=42.48C; Tm=30.98C).
In the case of F-SRNA (see a series of ON2s), this
modiﬁed ON seems to have a synergistic eﬀect of both
Scheme 2. (a)N H 3/EtOH, 808C then MeNH2, MeOH; (b)C H 3I, NaH,
DMF, –408C; (c) isobutyryl chloride, pyridine, –108C; (d) NaNO2,
aqueous AcOH then Et3N 3HF, Et3N, CH2Cl2;( e) DMTrCl, pyridine;
(f) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite chloride,
iPr2NEt, DMAP, CH2Cl2. Figure 2. Sequences of modiﬁed ONs.
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duplexes of FRNA2:cRNA2 and SRNA2:cRNA2
showed Tm values of 72.18C and 64.28C, respectively.
When FRNA2 (or SRNA2) was changed to F-SRNA2,
the duplex consisting of F-SRNA2:cRNA2 had the
highest Tm value of 76.18C. Therefore, the rank order of
the Tm’s with the complementary RNA (cRNA2) was
F-SRNA>FRNA>SRNA>MeRNA>RNA>DNA.
For the hybridization with cDNA2, F-SRNA showed
an intermediate value between FRNA and SRNA.
Although F-SRNA increased the Tm values with both
RNA and DNA in the same way as FRNA, the diﬀer-
ence in Tm values between F-SRNA2:cRNA2 and
F-SRNA2:cDNA2 was 24.48C. This diﬀerence was larger
than that between FRNA2:cRNA2 and FRNA2:cDNA2
(Tm=14.38C) and close to the diﬀerence between
SRNA2:cRNA2 and SRNA2:cDNA2 (Tm=30.88C).
From these results, it can be concluded that either
Me-SRNA or F-SRNA prefers RNA as a complementary
partner much more than DNA, which is similar to the
behavior of SRNA. In addition, F-SRNA, the hybrid of
FRNA and SRNA, formed the thermally most stable
duplex with RNA.
To investigate the structural aspects of the duplexes
consisting of the modiﬁed ONs, their CD spectra were
measured together with those of the natural duplexes.
As can be seen in Figure 3A, the CD spectrum of
RNA1:cRNA1 had a strong positive band near 260nm
and a negative band near 210nm, which is characteristic
of the A-conformation. Although the ellipticity at 260nm
of MeRNA1:cRNA1 was smaller than those of others,
all duplexes had a positive band near 260nm in each
CD spectrum, indicating therefore their A-form struc-
tures. In the CD spectra of a series of ON2:cRNA2
(Figure 3B), all duplexes also had strong positive bands
near 260nm, indicating that they adopt the A-form struc-
ture. When the sequence of complementary RNA (cRNA1
or cRNA2) was changed to the complementary DNA
(cDNA1 or cDNA2), the data suggests that all duplexes
adopt the A-like form similar to that of the natural
RNA:DNA duplex (Supplementary Data; Figure S1).
From these results, there were no obvious structural
changes in Me-SRNA and F-SRNA for their duplex for-
mation as was the case for SRNA, MeRNA and FRNA.
As mentioned in the Introduction section, a number of
sugar-modiﬁed ONs have been developed. However, few
are known to possess the type of modiﬁcation of the sugar
portion as do Me-SRNA (a combination of 20-OMe and
40-thio) and F-SRNA (a combination of 20-F and 40-thio).
To the best of our knowledge, the ON containing
20-deoxy-20-ﬂuoro-40-thioarabinouridine (40S-FANA; a
combination of 20-araF and 40-thio) is the only one
known having such a modiﬁcation pattern (21). Although
40S-FANA formed a duplex with its complementary RNA
in the A-form structure, the resulting duplex was fairly
destabilized thermally compared with the RNA:RNA
and FANA:RNA duplexes. Thus, no synergistic eﬀect in
terms of thermal stability was observed in 40S-FANA.
Contrary to 40S-FANA, both Me-SRNA and F-SRNA
formed a thermally stable duplex with the complementary
RNA. Several reasons have been suggested as to why
chemical modiﬁcation of ONs, such as 20-OMe, 20-F and
40-thio, improve their hybridization ability (5,10,22–25): (i)
formation of highly organized hydration: (ii) favorable
gauche and anomeric eﬀects: (iii) hydrophobic interactions
Figure 3. CD spectra of duplexes consist of ON1s:cRNA1 (A) and
ON2s:cRNA2 (B).
Table 1. Thermal stability of duplexes
a
With cRNAl or cRNA2 With cDNAl or cDNA2
ON Tm (8C) Tm (8C)
b Tm (8C) Tm (8C)
b
RNA1 66.2 – 51.6 –
DNA1 56.2  10.0 59.1 +7.5
MeRNAl 70.3 +4.1 52.0 +0.4
SRNA1 73.3 +7.1 43.6  8.0
Me-SRNAl 73.3 +7.1 42.4  9.2
FRNA1 77.4 +11.2 64.2 +12.5
RNA2 60.1 – 44.7 –
DNA2 50.1  10.0 49.5 +4.8
FRNA2 72.1 +12.0 57.8 +13.1
SRNA2 64.2 +4.1 33.4  11.3
F-SRNA2 76.1 +16.0 51.7 +7.0
MeRNA2 63.8 +3.7 42.4  2.3
aTm values were given as an average of three independent experiments.
bTm values were calculated based on the Tm values of RNA1:cRNA1
(RNA2:cRNA2) or RNA1:cDNA1 (RNA2:cDNA2).
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mation favoring C30-endo. In their
1H-NMR spectra
and crystal structural analysis, all nucleoside units of
Me-SRNA and F-SRNA are shown to prefer the
C30-endo conformation just as their 40-O-congener (18).
In this point, however, there is no additional rationale
for why 20-modiﬁed-40-thioRNA, especially F-SRNA,
improves and enhances their hybridization relative to the
individual chemical modiﬁcations. It is hoped that this will
be elucidated by crystal structural analysis, which is under
investigation, and will be reported elsewhere.
Nuclease stability
As described above, Me-SRNA and F-SRNA showed a
favorable hybridization with RNA arising from the hybrid
chemical modiﬁcation. Thus, we next investigated how
these modiﬁcations aﬀected their nuclease stability. As is
well known, MeRNA is highly resistant against ribo-
nuclease (RNase) digestion due to methylation of the
20-hydroxy groups. Furthermore, MeRNA also showed
higher stability against snake venom phosphodiesterase
(SVPD; a 30-exonuclease) and S1 nuclease (an endonu-
clease) compared with natural DNA (6). Since FRNA
also lacks the 20-hydroxy groups on its structure, this
modiﬁed ON was resistant against RNase digestion (26).
However, FRNA was degraded as easily as natural DNA
in calf serum, probably as a result of 30-exonuclease activ-
ity (5). For SRNA, this modiﬁed ON was highly resistant
against not only 30-exo- and endonucleases, but also in
human serum, despite possessing a 20-hydroxy group
on its structure (10,27,28). As mentioned above, we and
others have already reported the nuclease stability of
MeRNA, FRNA and SRNA, compared with natural
RNA and/or DNA. However, no comprehensive compar-
ison of their nuclease stability has been reported.
Accordingly, we evaluated in detail the nuclease stability
of Me-SRNA and F-SRNA along with that of MeRNA,
FRNA, SRNA, and natural RNA and DNA.
A series of ON1s and ON2s were labeled at the 50-end
with
32P and incubated in an appropriate buﬀer in the
presence of S1 nuclease (a typical endonuclease), SVPD
(a typical 30-exonuclease), and human plasma. The reac-
tions were then analyzed by PAGE under denaturing con-
ditions, and the half-lives (t1/2) were estimated based on
the ratio of full-length RNA at each time interval. The
results are summarized in Table 2. In the presence of S1
nuclease (0.17 U/ml), natural RNAs (RNA1 and RNA2)
and DNAs (DNA1 and DNA2) were all rapidly cleaved
to give t1/2 values of <1min (the results of PAGE are
presented in the Supplementary Data; Figure S2). To
our surprise, FRNAs (FRNA1 and FRNA2) were also
immediately cleaved, while MeRNAs (MeRNA1 and
MeRNA2) were completely stable (>24h) under the
same conditions. The SRNAs, SRNA1 and SRNA2,
showed moderate stability, giving t1/2 values of 76.8 and
12.6min, respectively, which were much higher than the
FRNAs. The stability of Me-SRNA and F-SRNA was
characteristic. Me-SRNA1 was completely stable as was
MeRNA1 (t1/2>24h). To clarify the order of stability,
MeRNA1 and Me-SRNA1 were treated in the presence
of a higher concentration of S1 nuclease (51 U/ml). As a
result, Me-SRNA1 was still stable under the conditions in
which MeRNA1 was cleaved to give a t1/2 of 224min
(136min for MeRNA2). On the other hand, F-SRNA2
was less stable than SRNA2 to give a t1/2 of 6.5min.
Thus, the rank order of S1 nuclease resistance was Me-
SRNA >> MeRNA >> SRNA > F-SRNA > FRNA >
RNA > DNA. For S1 nuclease stability, it can be con-
cluded that Me-SRNA showed a synergistic eﬀect of
MeRNA and SRNA, while F-SRNA did not show any
additive eﬀect.
We next compared the stability of each ON against
SVPD. Among the ONs examined, either natural ONs
(RNA1, RNA2, DNA1 and DNA2) or 20-modiﬁed ONs
(MeRNA1, MeRNA2, FRNA1 and FRNA2) were
cleaved to give t1/2 values of < 10min and there were no
obvious diﬀerences in their stability (the results of PAGE
are presented in the Supplementary Data; Figure S3).
In our experiment (under the reaction conditions and
sequences used), no resistance of MeRNAs against
Table 2. Comprehensive investigation of nuclease stability of chemically modiﬁed ONs
a
S1 nuclease SVPD 50% human plasma
ON t1/2
b t1/2
c t1/2 t1/2 Degradation pattern
RNA1 25.4 7.2s – 6.0 0.6min <10s Endo
DNAl 7.4 1.9s – 3.1 0.1min 46.8 7.0min Exo
MeRNAI >24h 224 47.6min 5.3 1.5min 187 22.6min Exo
SRNA1 76.8 25.2min – 54.4 2.5min 65.7 8.0min Endo
Me-SRNAl >24h >24h 79.2 8.7min 1631 60.8min Exo
FRNA1 1.1 0.1min – 5.8 l.2min 53.2 3.5min Exo
RNA2 13.0 2.4s – 4.3 0.4min <10s Endo
DNA2 6.6 1.3s – 2.7 0.3min 31.0 1.7min Exo
FRNA2 20.8+0.4s – 6.0 1.0min 51.9 3.1min Exo
SRNA2 12.6 1.7min – 12.8 3.5min <10s Endo
F-SRNA2 6.5 0.5min – 21.0 3.6min 120 10.5min Exo
MeRNA2 >24h 136 11.5min 4.5 1.1min 435 12.9min Exo
aErrors reﬂect standard deviation from three independent experiments.
bONs were treated with 0.17U/mL S1 nuclease.
cONs were treated with 51U/mL S1 nuclease.
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which 20-O-methyl RNAs showed high stability against
SVPD (6). Our results showed that SRNAs (SRNA1
and SRNA2) are more stable than MeRNA and FRNA.
In addition, modiﬁcations of the 20-hydroxy group of
SRNA, i.e. Me-SRNA and F-SRNA, improved their sta-
bility, resulting in the following approximate rank order of
SVPD resistance was Me-SRNA>F-SRNA>SRNA>
MeRNA, FRNA, RNA and DNA. To develop chemically
modiﬁed ONs for therapeutic applications, the ONs
should be stable in the bodily ﬂuids. Thus, ﬁnally, we
investigated the stability of ONs in 50% human plasma.
Under these conditions, RNA1 was rapidly cleaved
(t1/2<10s), while DNA1 was much more stable
(t1/2=46.8min). Even in our sequence, MeRNA1 was
more stable than DNA1 (6), and the stability of FRNA1
was rather close to DNA1 (5). As we reported, SRNA1
was also relatively stable (10), and it was found that
SRNA1 was slightly more stable than FRNA1. As can
be seen, the stability of Me-SRNA1 was signiﬁcantly
improved in human plasma (t1/2=1631min), with the
rank order of stability in plasma being Me-SRNA >>
MeRNA>SRNA>FRNA>DNA >>RNA. In the
case of one series of ON2s, SRNA2 was unexpectedly
unstable and the stability was the same as that of natural
RNA2. When the 20-hydroxy groups of SRNA2 were
ﬂuorinated, the stability of the resulting F-SRNA2 was
signiﬁcantly improved to give a t1/2 of 120min, which
was longer than that of FRNA2. From these results,
both Me-SRNA and F-SRNA showed a synergistic
improvement with respect to their nuclease stability with
one exception (F-SRNA2 against S1 nuclease).
As shown above, we have carried out the comprehen-
sive comparison of nuclease stability of chemically mod-
iﬁed ONs. Throughout this investigation, the rank order
of stability was proposed. In the presence of human
plasma, the high stability of Me-SRNA is worth noting.
In addition, it was suggested that the stability of MeRNA
is higher than FRNA, and that the stability of SRNA is
drastically aﬀected by sequence context. Since human
plasma will include multiple nucleases, the degradation
pattern of each of the ONs was analyzed based on the
results of PAGE. As shown in Figure 4, RNAs were
cleaved at a certain position to aﬀord several shorter frag-
ments, which is a consequence of endonuclease activity
(probably RNase activity) in human plasma. On the
other hand, DNAs aﬀorded fragments corresponding to
n 1 and n 2( n=full-length). This mode of degrada-
tion can be explained by 30-exonuclease activity, which is
recognized as one of the major factors in ON digestion
(29). In addition, one shortest fragment also appeared
along with these 30-exonuclease products. Although we
did not determine its structure, we assume it is a labeled
phosphate or 50-monophosphate, which is digested from
the 50-end. Since the 20-hydroxy groups are substituted in
MeRNAs and FRNAs, these modiﬁed ONs were resistant
against digestion by endonucleases such as RNase and
digested gradually by 30-exonuclease activity, whereas
SRNAs were digested by RNase because of the existence
of the 20-hydroxy groups. Both Me-SRNA and F-SRNA
were digested by 30-exonuclease. Therefore, the higher sta-
bility of Me-SRNA and F-SRNA is thought to arise from
the acquisition of endonuclease resistance relative to
SRNA, and improvement of exonuclease resistance,
Figure 4. Hydrolysis pattern of ONs in 50% human plasma. See Materials and methods section for experimental conditions.
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tive to MeRNA and FRNA. The sequence context of each
strand might explain the diﬀerent stability in human
plasma shown by SRNA1 and SRNA2. In serum (prob-
ably also in plasma), RNA analogs are predominantly
digested by the contribution of RNase A-like activity
(30). RNase A is an endonuclease that speciﬁcally hydro-
lyzes RNA after pyrimidine residues. The preference order
of cleavage of this enzyme isolated from the pancreas is:
UpA>CpA>UpG and CpG>CpC, UpC, CpU and
UpU (31). As can be seen in the degradation pattern of
SRNA2, this ON is immediately cleaved at the single posi-
tion between the U(6) and the A(7) positions (UpA)
(Supplementary Data; Figure S4). In RNA2, this position
was also the major site of cleavage. In contrast, SRNA1
does not have UpA in the sequence, and thus showed
higher stability in human plasma. Our results indicate
that the UpA sequence is the most cleavable site in
human plasma. This information would be helpful in
designing RNA therapeutic molecules.
Thus far, a large number of chemically modiﬁed ONs
have been synthesized and their stability against nucleases
has been evaluated. Although active site and proposed
mechanism of cleavage by nuclease S1 and SVPD used
in this study have been suggested (32–34), it is still unclear
what kind of chemical modiﬁcation of ONs appends the
nuclease resistance. Our comprehensive comparison indi-
cated useful information on the structural requirement for
the nuclease resistance. Under conditions in which natural
RNA and DNA rapidly cleaved, FRNA was also cleaved
similarly by S1 nuclease. In contrast, MeRNA remained
completely intact under the same conditions. Cummins
et al. reported that the stability against S1 nuclease
imparted by 20-modiﬁcations correlated with the size of
the modiﬁcation (6). Our results indicate that a drastic dif-
ference in S1 nuclease resistance may exist between ﬂuoro
and methoxy substituents at the 20-position. In SRNA, this
modiﬁed ON showed higher stability than RNA, which
would arise from structural changes of the sugar ring.
These considerations would account for the highest stabil-
ity of Me-SRNA and lesser stability of F-SRNA versus
SRNA. Although F-SRNA was more stable than FRNA
because of its 40-thiosugar construction, this ON was less
stable than SRNA due to a smaller substituent at the
20-position (–OH versus –F). We also examined the stabil-
ity of 40-thioDNA (SDNA1; 50-AGTCCGAATTCAC
GT-30) against S1 nuclease, and its t1/2 was estimated to
be 19.4min (the result of PAGE is not shown), which was
shorter than that of SRNA1 (–OH versus –H). This data
also supported our proposal for S1 nuclease stability. As
for the stability against SVPD, there was no obvious dif-
ference in RNA, DNA, MeRNA and FRNA. Since SRNA
and Me-SRNA were more stable than others, the
40-thiosugar construction appeared to be a major contri-
buting factor in the resistance. In human plasma (or
serum), ONs possessing 20-OH groups are rapidly cleaved
by RNase activity. Therefore, the 20-OH groups of chem-
ically modiﬁed ONs are mostly substituted, and this type of
substitution appended complete resistance to RNase
digestion. However, chemically modiﬁed ONs such
as MeRNA and FRNA are generally digested by
30-exonucleolytic cleavage. Our results indicated that
the 20-O-methylation of SRNA was imparted the highest
resistance toward endonucleolytic cleavage, and the
40-thiolation of MeRNA gave the highest resistance
toward exonucleolytic cleavage. From the standpoint of
nuclease stability, Me-SRNA showed a synergistic
improvement and was extremely stable in human plasma.
CONCLUSION
In this article, we have synthesized 20-modiﬁed-
40-thioRNA, i.e. 20-ﬂuoro-40-thioRNA (F-SRNA) and
20-O-Me-40-thioRNA (Me-SRNA). These ONs consist of
a hybrid chemical modiﬁcation, and were expected to
show synergistic improvement for their hybridization
and nuclease stability. Concerning the hybridization,
F-SRNA exhibited synergistic improvement to show the
highest Tm value in duplex formation with a complemen-
tary RNA. Although there was no obvious improvement
in the Tm values for Me-SRNA, this modiﬁed ON has the
advantages of a much more favorable duplex formation
with a complementary RNA than with the complementary
DNA, which is arising from the character of 40-thioRNA
(SRNA). Nuclease stability is the most important aspect
in developing the chemically modiﬁed ONs. Thus, we have
carried out a comprehensive comparison of nuclease
stability of F-SRNA and Me-SRNA, along with FRNA,
MeRNA, and natural RNA and DNA. F-SRNA was less
stable than MeRNA in human plasma, while Me-SRNA,
perhaps one of the most stable ONs, was signiﬁcantly
stable under the same conditions. From these results,
Me-SRNA should be a versatile modiﬁed ON applicable
to antisense molecules against miRNA and siRNA strate-
gies. Further investigations are underway.
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Supplementary Data are available at NAR Online.
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